Jeffrey A. Cohen

Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

2017 | 1. lékařská fakulta, 2. lékařská fakulta

Publikace